New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.
about
Remodelling the extracellular matrix in development and diseaseThe significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosisSelective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal CancerPre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screeningDirect expression of active human tissue inhibitors of metalloproteinases by periplasmic secretion in Escherichia coli.Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities.Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastomaMatrix metalloproteinase-14 both sheds cell surface neuronal glial antigen 2 (NG2) proteoglycan on macrophages and governs the response to peripheral nerve injuryNew strategies for targeting matrix metalloproteinasesIdentification of Reprogrammed Myeloid Cell Transcriptomes in NSCLCSelective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal diseaseAn engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesisMechanotransduction and cartilage integrity.Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP.Invading one step at a time: the role of invadopodia in tumor metastasis.Monitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.Therapeutic modulation of prostate cancer metastasis.The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.Clonal cooperativity in heterogenous cancers.MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer.Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies.Ovarian Cancer Cell Adhesion/Migration Dynamics on Micro-Structured Laminin Gradients Fabricated by Multiphoton Excited Photochemistry.Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles.Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8.Direct production of functional matrix metalloproteinase--14 without refolding or activation and its application for in vitro inhibition assays.Development of a periplasmic FRET screening method for protease inhibitory antibodies.Differentiated expression of membrane type metalloproteinases (MMP-14, MMP-15) and pro-MMP2 in laryngeal squamous cell carcinoma. A novel mechanism.Zymography as a Research Tool in the Study of Matrix Metalloproteinase Inhibitors.Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.Functional Production of Catalytic Domains of Human MMPs in Escherichia coli Periplasm.Computational Approaches to Matrix Metalloprotease Drug Design.Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.
P2860
Q26864798-1DEBA137-7C16-4A8E-8F3E-4B3FAC0F4EFAQ27009126-55249F6E-9294-4B63-9722-F19DCD85205CQ27306938-F0E4FB8E-1696-41D0-9451-85408C757CACQ28394124-03B6E4D4-9066-43DB-ABE9-42F5DA46CE01Q33617768-821D81F9-BF8D-43FC-B957-0D31564C5593Q33815397-FE3DD29F-D762-42F2-9235-F631BE940965Q33816188-DE03A635-CAB7-43C4-A0B1-DE105C50B28FQ35055608-0968DDC3-CD26-4E10-ABA6-AE330642B774Q35544060-2808B50A-053C-4357-8829-CAA77934DAF5Q35654027-0CFE4460-3827-485F-9B66-73145766E92FQ36190097-6BF2B827-EB7E-4240-A076-EE72D040B08AQ36307495-C42BDDE1-E89A-4916-ADFE-BCE523504B51Q36413450-3CD3043E-BF3B-4C9E-A98D-C15216943C97Q36760245-BFE9F033-2F62-4F6E-9C34-C7EF1E27DB2FQ37224415-D0EF9EE1-177E-4CF6-90E6-BD1EFF2DA1E2Q37282934-CDA8199A-B12C-4F71-A9E0-D0AB5247A102Q37432524-FBBF8C8B-6DF5-46F2-A6C2-2301E796FAA9Q37614524-FE23E85E-3EB2-485B-88B4-37ACEEC5D9B8Q37672635-77905897-6C4B-45ED-9CAA-DF24AD6F0EF0Q37693503-5EC4CBAB-EA35-4447-B47E-155E4BB6E744Q38182140-41D85DBB-B89C-4A7C-93AE-131222374A09Q38192005-BFA36E3D-7EAE-444B-B46E-68779BCF7CD1Q38201795-AEFFE144-E3D2-4D9A-9609-B50234DD43E5Q38881849-E4ED1414-DC17-467F-B8B8-535777CD54B4Q38943125-473B63F0-4D04-47D0-A778-E1091BF15BA1Q39066534-85E15D49-776D-453D-9482-D007F43C16FEQ39249230-9E5C5AB4-17D4-4409-900F-C593DFE4B875Q41704632-1FEA262B-EDF4-41AB-A83F-19B59AC00905Q42364091-551B70A7-9904-466C-B196-44CD9384822EQ42571449-8041EE74-2CD2-4016-854E-37185956F21AQ45950974-F877F3E0-BA12-4096-B0DD-0C9EBBDEE0F9Q46033483-F7A1547C-8D04-4855-BA48-678D05218F6EQ46037583-9E530961-159A-463B-85C4-C5826E115BC5Q47117984-FC08FB4F-BFEF-4DF9-8FF6-11D87F708FC9Q50109651-E50C0D57-8509-4069-934C-ADCEF324A2A4Q50109720-A0629476-1970-44C1-B9C2-B3DCFAA1913EQ51097569-7D910A01-F0D1-4880-B0D0-0F9DD036536AQ51155840-FEDE5A87-288A-4FDE-B9F1-C99F8FE68594
P2860
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New Strategies for the Next Ge ...... s with Therapeutic Antibodies.
@en
New Strategies for the Next Ge ...... s with Therapeutic Antibodies.
@nl
type
label
New Strategies for the Next Ge ...... s with Therapeutic Antibodies.
@en
New Strategies for the Next Ge ...... s with Therapeutic Antibodies.
@nl
prefLabel
New Strategies for the Next Ge ...... s with Therapeutic Antibodies.
@en
New Strategies for the Next Ge ...... s with Therapeutic Antibodies.
@nl
P2860
P356
P1476
New Strategies for the Next Ge ...... s with Therapeutic Antibodies.
@en
P2093
Daniel T Dransfield
Laetitia Devy
P2860
P304
P356
10.1155/2011/191670
P577
2010-10-28T00:00:00Z